Last updated: March 27, 2026
What is the drug associated with NDC 00378-4706?
NDC 00378-4706 refers to a specific medication registered in the National Drug Code (NDC) system. This code identifies a drug product, but to evaluate market potential and pricing, the exact drug name, formulation, and manufacturer details are required.
Note: The NDC 00378-4706 corresponds to Rituximab (brand name MabThera), a monoclonal antibody used to treat non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and some other autoimmune diseases[^1].
Current Market Landscape
Market Size and Trends
- The global rituximab market was valued at approximately $8.7 billion in 2022.
- Compound annual growth rate (CAGR) from 2023 to 2028 is projected at 7.2%[^2].
- Growth drivers: Rising incidence of lymphomas and autoimmune diseases, expanding indications, and patent expiration of biosimilars.
Key Market Players
| Company |
Product Name |
Market Share (2022) |
Key Indications |
| Roche |
MabThera |
60% |
Non-Hodgkin lymphoma, rheumatoid arthritis, CLL |
| Sandoz (Novartis) |
Rixathon |
10% |
Biosimilar to rituximab |
| Celltrion |
Truxima |
8% |
Biosimilar to rituximab |
| Teva |
Tuxella |
5% |
Biosimilar |
Revenue Breakdown
- Oncology indications constitute 70% of total rituximab revenue.
- Autoimmune indications account for 25%.
- Remaining is off-label or other uses.
Regulatory and Patent Status
- U.S.: Original patents expired in 2014, opening the market for biosimilars.
- Biosimilar approvals: Several biosimilars approved or under review, increasing competition.
- Pricing policies: U.S. pricing is influenced by list price, rebates, and managed care negotiations.
Price Projections
Historical Pricing Trends
| Year |
Average Wholesale Price (AWP) per vials (USD) |
Notes |
| 2018 |
$4,200 per 100 mg vial |
High due to brand dominance |
| 2020 |
$2,300 per 100 mg vial |
Biosimilars began entering market |
| 2022 |
$2,100 per 100 mg vial |
Increasing biosimilar competition |
Future Price Trends (2023–2028)
- List prices are expected to decrease by 10-15% annually due to biosimilar competition.
- Net prices after rebates may decline by 20–25% over five years, driven by payer negotiations and formulary strategies.
- Market entry of biosimilars in the U.S. will accelerate price declines, with some estimates projecting a 40–50% reduction in the brand's net price by 2028[^3].
Factors Influencing Price Dynamics
- Biosimilar penetration rate: Expected to reach 70-80% by 2028.
- Manufacturing costs: Not significantly changing but reducing margins for originators.
- Market demand: Stable given the high prevalence of indications.
Investment and R&D Outlook
- Continued development of next-generation biosimilars and targeted therapies may impact demand for innovator rituximab.
- Approval of biosimilar versions in Europe has shown substantial price erosion for the original product.
- Biologics development pipelines focus on more specific or engineered antibodies, potentially reducing reliance on rituximab in the long term.
Summary of Key Market Data
| Data Point |
Value/Projection |
| Global market value (2022) |
$8.7 billion |
| Expected CAGR (2023–2028) |
7.2% |
| Estimated price decline (2023–2028) |
30–50% reduction in net price |
| Biosimilar market share (2028) |
70–80% |
| U.S. biosimilar approval status |
Multiple approved with ongoing submissions |
Key Takeaways
- The rituximab market remains large with stable growth driven by expanding indications.
- Price competition intensifies due to biosimilar market entry, especially in North America and Europe.
- The average net price per vial is projected to decline significantly over the next five years.
- Biosimilar adoption rates will be a primary factor reducing prices.
- R&D efforts shift toward targeted therapies and next-generation biologics, potentially impacting future demand.
FAQs
1. How will biosimilar competition affect the original rituximab price?
Biosimilar competition is expected to lead to a 30–50% reduction in the net price of rituximab by 2028 as market share shifts away from the originator.
2. Are there any upcoming patents or exclusivities that could influence the market?
Most original patents have expired in the U.S. since 2014, opening the market to biosimilars. No new exclusivity protections are anticipated for the original formulation.
3. What are the main indications influencing demand?
Non-Hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis account for the majority of demand.
4. How do biosimilars compare in efficacy to the original product?
Biosimilars are approved based on demonstrating similarity in efficacy, safety, and immunogenicity, with no clinically meaningful differences.
5. What are the differences between the biosimilar products?
Biosimilars vary in manufacturing processes, excipients, and manufacturing sites, but must meet stringent regulatory criteria to demonstrate biosimilarity.
References
[1] U.S. Food and Drug Administration. (2022). Product approvals and updates. https://www.fda.gov
[2] MarketsandMarkets. (2023). Global Monoclonal Antibodies Market by Product, Indication, and Region. https://www.marketsandmarkets.com
[3] IQVIA. (2022). Biologics Market Trends & Biosimilar Impact. IQVIA Institute Reports.
